[Anti-arrhythmia efficacy of propafenone per os in the prevention of paroxysmal supraventricular arrhythmia resistant to class Ia agents].
The efficacy of orally administered propafenone in the prevention of paroxysmal supraventricular dysrhythmias (atrial fibrillation, atrial tachysystole, reciprocal tachycardia) resistant to Vaughan-Williams class Ia drugs was investigated in 10 patients. Propafenone controlled dysrhythmia very well in 4 out of the ten patients, and satisfactorily in another one at a dosage ranging from 450 to 900 mg/day in 3 or 4 divided doses; this result was documented using continuous 24 hr. Holter ECG monitoring. Among the 5 clinical failures, 1 patient had atrial fibrillation primarily at night, and another poorly tolerated this agent which led to interrupt therapy.
Boutaud
P
P
Service de Cardiologie, CHU de Poitiers.
Guillem
J P
JP
Maarek-Charbit
M
M
Amiel
A
A
Ciber
M
M
Herpin
D
D
Demange
J
J
D000284:Administration, Oral; D000368:Aged; D004206:Disopyramide / Q000627:therapeutic use; D004341:Drug Evaluation; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011405:Propafenone / Q000008:administration & dosage / Q000627:therapeutic use*; D011802:Quinidine / Q000627:therapeutic use; D013614:Tachycardia, Paroxysmal / Q000517:prevention & control*; D013617:Tachycardia, Supraventricular / Q000517:prevention & control*
D011405:Propafenone; D004206:Disopyramide; D011802:Quinidine
Efficacité antiarythmique de la propafénone per os dans la prévention des arythmies paroxystiques supraventriculaires résistantes aux agents de la classe Ia.